FAST: Foundation for Angelman Syndrome Therapeutics

Latest from FAST: Foundation for Angelman Syndrome Therapeutics

Orphan Drug Designation Granted to CLN2 Form of Batten Disease, RGX-181

November 17, 2018

Article

Here’s a round-up of recent designations granted by the FDA to products developed to treat rare diseases.

FDA Grants Fast Track Designation to A4250 for Progressive Familial Intrahepatic Cholestasis

October 24, 2018

Article

Here’s a round-up of recent designations granted by the FDA to products developed to treat rare diseases.

Blood Clot Treatment Fast-tracked By FDA

September 27, 2018

Article

The FDA recognized the potential of proCase, which is being developed to treat blood clots and does not increase the risk of bleeding.

Miransertib Granted Fast Track Designation for Treatment of PIK3CA-Related Overgrowth

September 17, 2018

Article

The FDA has granted a fast track designation to miransertib for the treatment of PIK3CA-Related Overgrowth Spectrum, a group of ultra-rare genetic disorders.

Fast Track Designation Granted to Idiopathic Pulmonary Fibrosis Treatment, Pamrevlumab

September 12, 2018

Article

The FDA has granted a fast track designation to pamrevlumab for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

FDA Grants Fast Track Designation to Bullous Pemphigoid Treatment, Bertilimumab

September 11, 2018

Article

The FDA has granted a fast track designation to Immune Pharmaceuticals, Inc.’s bertilimumab for the treatment of bullous pemphigoid.